Today, May 16th, is Mental Health Action Day. Xenon's employee-led Mental Wellness Committee hosted walks in Boston, Vancouver, and remote locations last Thursday to raise awareness for Mental Health Month and highlight the positive impacts of exercise on mental health! #MentalHealthMonth #XENEDreamTeam #CompassionConnects #BeSeenInGreen
Xenon Pharmaceuticals Inc.
Biotechnology Research
Burnaby, BC 13,672 followers
A neuroscience-focused biopharmaceutical company
About us
Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship azetukalner program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic-clonic seizures. In 2024, we are planning to initiate a Phase 3 azetukalner program in major depressive disorder, based on topline data from our Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
- Website
-
http://www.xenon-pharma.com
External link for Xenon Pharmaceuticals Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Burnaby, BC
- Type
- Public Company
- Specialties
- drug discovery, ion channels, neurology, epilepsy, drug development, neuroscience, biotechnology, biopharmaceuticals, seizures, focal onset seizures, MDD, psychiatry, depression, neuropsychiatry, tonic-clonic seizures, FOS, PGTSC, sodium channels, and potassium channels
Locations
-
Primary
Get directions
3650 Gilmore Way
Burnaby, BC V5G 4W8, CA
-
Get directions
117 Kendrick Street
Suite 200
Needham, MA 02494, US
Employees at Xenon Pharmaceuticals Inc.
Updates
-
Xenon Pharmaceuticals Inc. is experiencing exciting #growth across the US! Join our #MedicalAffairs team as a regional Medical Science Liaison. Learn more: https://lnkd.in/gYEwkyi5 #neuroscience #neurology #epilepsy #biotechjobs #pharmaceuticaljobs
-
-
Our CEO Ian Mortimer was interviewed today on BiotechTV discussing Xenon's work in #epilepsy and major depressive disorder (#MDD). We are also leveraging our extensive ion channel expertise to develop new product candidates, such as #Kv7 channel openers, #Nav1.7 inhibitors and #Nav1.1 openers. Full video can be found here: https://lnkd.in/gTExAwdT
𝐑𝐁𝐂 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Xenon Pharmaceuticals Inc.'s CEO Ian Mortimer on Kv7 potassium channel modulation in the CNS space and his thoughts on NaV1.7/1.8 for pain. He gives the rationale for Kv7 in epilepsy and major depressive disorder, and explains why Xenon has chosen the NaV1.7 sodium channel in over NaV1.8 for pain. Full video: https://lnkd.in/gTExAwdT
-
The Xenon Pharmaceuticals Inc. team was proud to be part of a history-making day at #Fenway Park, joining 2,000 #walkers to raise funds and awareness for #epilepsy. Thank you Epilepsy Foundation New England for organizing this amazing event! #BostonWalkforEpilepsy #XENEDreamTeam
-
It was a beautiful day yesterday for the Xenon Pharmaceuticals Inc. #XENEDreamteam at the #VancouverSunRun! In addition to sponsoring a water station for the 2.5K Mini Race, we contributed $5,000 to the BC Epilepsy Society. Thank you to all the Xenon volunteers and runners who made this event so special! #epilepsy #XenonGives #XenonCares #XenonMoves
-
Xenon Pharmaceuticals Inc. is proud to be a gold sponsor of the upcoming #Boston Walk for #Epilepsy hosted by Epilepsy Foundation New England! The event is just over 1 week away... Learn more here: https://lnkd.in/gJJFXtAR
Thank you to Xenon Pharmaceuticals Inc. and UCB for being Gold Sponsors at our Boston Walk. Your partnership is instrumental in advancing our mission at Epilepsy Foundation New England. With your support, we continue to make strides in overcoming the challenges faced by those living with epilepsy in our community. Learn more about our walk and register today: https://bit.ly/47lq5PN #BostonWalk #EpilepsyAwareness #MakeEpilepsyHistory
-
-
Today is the last day to visit Xenon Pharmaceuticals Inc. at Booth 1797 in the #AANAM Exhibit Hall before it closes at 4:00 pm! Thank you to everyone who connected with us at the booth, the 5K run, and meeting sessions. @AANmember
-
Xenon Pharmaceuticals Inc. was proud to be one of the sponsors of the 5K Run/Walk for Brain Research at #AANAM this morning. Our #XENEDreamTeam was all smiles (despite the early, cold start) and finished strong! CJ Park, PharmD Risa Torkin, PhD Joe McIntosh Lauren Corry, PharmD, RPh-I Elisabeth Vivaldi @AANmember #neuroscience #neurology #brainresearch
-
Xenon Pharmaceuticals Inc. has two oral presentations related to #XEN1101 scheduled this afternoon at #AAN24! We hope you can join us at session 19 "Epilepsy Clinical Trials and Long-term Studies." 4:06 pm - Dr. Roger Porter: "The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)" 4:18 pm - Dr. Jacqueline French: “Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy.” Learn more: https://lnkd.in/gDF6k-e5 #epilepsy #neurology #clinicaltrials #therapeutics #XTOLE #AANAM @AANmember
-
The Xenon Pharmaceuticals Inc. team is at the the American Academy of Neurology Annual Meeting in Denver, Colorado. If you're attending #AAN24, stop by Booth #1797 to learn more about #XEN1101 and our #neurology pipeline! #XENEDreamTeam #neuroscience #epilepsy #MDD #AANAM @AANmember